A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients

Endocrine Practice

Volumn 18, Issue 5, 2012, Pages 712-719

  Dhital, Subarna M ^a   Shenker, Yoram ^a   Meredith, Melissa ^a   Davis, Dawn Belt ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; PREDNISONE;

ADULT; AGED; BODY MASS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; RACE; RETROSPECTIVE STUDY; REVIEW;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES;

EID: 84867343810     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11371.OR     Document Type: Review

References (22)

1. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyper-glycemia. Endocr Pract. 2009;15:469-474.
2. Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F. Effect of dexamethasone on oral glucose tolerance in nor-mal individuals. Endocr Pract. 2010;16:770-777.
3. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large popu-lation. Diabetes Care. 2006;29:2728-2729.
4. Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA. Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract. 2006;12:358-362.
5. Moore R, Ravindran V, Baboolal K. The burden of new-onset diabetes mellitus after transplantation. Clin Transplant. 2006;20:755-761.
6. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infec-Tion rate in diabetic patients. JPEN J Parenter Enteral Nutr. 1998;22:77-81.
7. Malmberg K, Norhammar A, Wedel H, Rydén L. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-Term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. 1999; 99:2626-2632.
8. Bloom RD, Crutchlow MF. Transplant-Associated hyper-glycemia. Transplant Rev (Orlando). 2008;22:39-51.
9. Inzucchi SE. Clinical practice. Management of hyper-glycemia in the hospital setting. N Engl J Med. 2006;355: 1903-1911.
10. Menzin J, Korn JR, Cohen J, et al. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. J Manag Care Pharm. 2010;16:264-275.
11. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: An independent marker of in-hospital mortality in patients with undiagnosed diabe-Tes. J Clin Endocrinol Metab. 2002;87:978-982.
12. Hoogwerf B, Danese RD. Drug selection and the manage-ment of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 1999;25:489-505.
13. Braithwaite SS, Barr WG, Thomas JD. Diabetes man-Agement during glucocorticoid therapy for nonendocrine disease. Endocr Pract. 1996;2:320-325.
14. Lucidi P, Porcellati F, Rossetti P, et al. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insu-lins NPH, glargine, and detemir after 1 week of daily admin-istration at bedtime in type 2 diabetic subjects: A random-ized cross-over study. Diabetes Care. 2011;34:1312-1314.
15. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7:188-199.
16. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient man-Agement of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30:2181-2186.
17. Bazzano LA, Lee LJ, Shi L, Reynolds K, Jackson JA, Fonseca V. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: A meta-Analysis of randomized controlled trials. Diabet Med. 2008;25:924-932.
18. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35 (Suppl 1):S11-S63.
19. Umpierrez GE, Hellman R, Korytkowski MT, et al Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: An endo-crine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16-38.
20. Holman RR, Farmer AJ, Davies MJ, et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med. 2009;361:1736-1747.
21. King AB. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: A crossover, double-blind, and randomized study using continuous glucose monitor-ing. J Diabetes Sci Technol. 2010;4:151-154.
22. Monami M, Marchionni N, Mannucci E. Long-Acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-Analysis. Diabetes Obes Metab. 2009;11:372-378.